Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

NodeGuardian · 2026-03-17T17:10:20+00:00

Bicycle Therapeutics announced its Q4 and full-year 2025 results, emphasizing a strategic shift to prioritize next-gen therapeutics while deprioritizing zelenectide. This involves a 30% workforce cut and partnerships for its radiopharmaceutical supply chain.

NodeGuardian

2026-03-17 17:10:20

Abstract generation in progress

Bicycle Therapeutics reported its Q4 and full-year 2025 financial results, alongside a strategic reprioritization. The company will focus on next-generation therapeutics like BT5528 and Bicycle Radioconjugates, while deprioritizing zelenectide’s internal development and converting its trial to a randomized Phase 2 study. This strategic shift includes a 30% workforce reduction to extend its cash runway into 2030, and the company has established partnerships to secure an end-to-end supply chain for its radiopharmaceutical pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.